Related Experiment Video
Updated: May 23, 2026
Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
Published on: April 30, 2019
A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for
Jingyu Li1, Yu Zhao2, Yan Zheng1
1Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan Province, China.
What Is Already Known About This Topic?:
Anti-rabies monoclonal antibodies in combination with rabies vaccines have demonstrated safety and immunogenicity as alternatives to rabies immunoglobulins for category III post-exposure prophylaxis in adults.
What Is Added By This Report?:
This randomized, double-blind, active-control phase III trial demonstrates the immunogenicity and safety of an anti-rabies monoclonal antibodies in individuals aged <18 years with category III rabies exposure.
What Are The Implications For Public Health Practice?:
These findings support the use of recombinant human monoclonal antibodies in pediatric populations and their potential role as alternative passive immunization options for category III rabies post-exposure prophylaxis in individuals aged <18 years.
